The combination of ST80 with anti–PD-L1 therapy shows promise in preclinical models (3), however, the potential synergistic effects of ST80 with other immunotherapeutic agents, conventional chemotherapy, and the impact of OTUD4/CD73 axis blockade in other cancers remain to be explored. Here, OTUD4 is linked to cancer.